Navamedic ASA provided revenue guidance for the first half of 2022. The company has decided to provide a trading update based on estimated organic revenue growth for the first half of 2022 in excess of 30%. The high revenue growth is a result of a strong June 2022 and is driven by significant demand for Mysimba as well as other key products in the portfolio.